Charles River Laboratory executives said they continue to expect the North American research model business volume to decline, and expenses for academic and government customers are limited by the US National Institutes of Health's flat budget and the slow funding approval process.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.